Bloem BR, Okun MS, Klein C. Parkinson's disease. Lancet 2021;397(10291):2284–2303. DOI: 10.1016/S0140-6736(21)00218-X
Armstrong MJ, Okun MS. Diagnosis and treatment of parkinson disease: a review. JAMA 2020;323(6):548–560. DOI: 10.1001/jama.2019.22360
Scott LJ. Opicapone: a review in Parkinson's disease. CNS Drugs 2021;35(1):121–131. DOI: 10.1007/s40263-020-00778-6
Jost WH, Kulisevsky J, LeWitt PA. Inhaled levodopa for threatening impending OFF episodes in managing Parkinson's disease. J Neural Transm (Vienna) 2023;130(6):821–826. DOI: 10.1007/s00702-023-02636-3
Müller T. The role of istradefylline in the Parkinson's disease armamentarium. Expert Opin Pharmacother 2023;24(7):863–871. DOI: 10.1080/14656566.2023.2201374
Aleid A, Aleid M, Alehaiwi G, et al. Advancements in the clinical outcomes of functional neurosurgery with deep brain stimulation for movement disorders: a literature review. Cureus 2023;15(6):e40350. DOI: 10.7759/cureus.4035
Martínez-Fernández R, Natera-Villalba E, Máñez Miró JU, et al. Prospective long-term follow-up of focused ultrasound unilateral subthalamotomy for Parkinson disease. Neurology 2023;100(13):e1395–e1405. DOI: 10.1212/WNL.0000000000206771
Cheng Y, Tan G, Zhu Q, et al. Efficacy of fecal microbiota transplantation in patients with Parkinson's disease: clinical trial results from a randomized, placebo-controlled design. Gut Microbes 2023;15(2):2284247. DOI: 10.1080/19490976.2023.2284247
Vivacqua G, Mason M, De Bartolo MI, et al. Salivary α-synuclein RT-QuIC correlates with disease severity in de novo Parkinson's disease. Mov Disord 2023;38(1):153–155. DOI: 10.1002/mds.29246
Menon S, Armstrong S, Hamzeh A, et al. Alpha-synuclein targeting therapeutics for Parkinson's disease and related synucleinopathies. Front Neurol 2022;13:852003. DOI: 10.3389/fneur.2022.852003
